Using SMART Regimens in PM

PHM Session: Get SMART: Implementation of updated asthma guidelines for pediatric hospitalists Presenters: Alexander Hogan, MD, MS, Connecticut Children’s Medical Center, Hartford, Conn., Kathryn Kyler, MD, MSc, and Claire Seguin, MD, Children’s Mercy Kansas City, Mo. This session focused on how pediatric hospitalists can improve the asthma care of patients discharged from hospitalizations by instituting single maintenance and reliever therapy (SMART) regimens. More specifically, this is a single inhaler that includes both an inhaled corticosteroid (ICS) and a long-acting beta-agonist (LABA), which have U.S. Food and Drug Administration-approved formulations as budesonide/formoterol (Symbicort) and mometasone/formoterol (Dulera). SMART regimens for asthma are based on the expert panel report (EPR) update, EPR-4, released by the National Asthma Education and Prevention Program Coordination Committee. The key SMART-specific recommendations discussed by the presenters for patient subsets were: For patients over 4 years of age: moderate or severe persistent asthma should be preferentially treated with low- or moderate-dose ICS/formoterol daily and quick-relief therapy, as compared to ICS/LABA plus as-needed (PRN) short-acting beta-agonist (SABA), or high-dose ICS plus PRN SABA. For patients over 12 years of age: moderate or severe persistent asthma should be preferentially treated with ICS/formoterol as daily and quick-relief therapy, as compared to higher-dose ICS/LABA dail...
Source: The Hospitalist - Category: Hospital Management Authors: Tags: Adolescent Medicine Asthma Clinical Guidelines Pediatrics Source Type: research